Trivitron buys Ani Labsystems for €15.8 mln
Trivitron Healthcare Private Limited has acquired Finnish diagnostics technology company Ani Labsystems for €15.8 million (Rs 110 crore).
With this acquisition, Trivitron enters into the Point of Care Diagnostics, Immuno Diagnostics and Molecular Diagnostics. These three areas are the fastest growing in the in vitro diagnostics field.
The Finnish diagnostics technology company is a group of companies including Ani Biotech, Ani Labsystems, Biopoint and K3. Trivitron has bought all these companies and will merge them into Labsystems Diagnostics OY, a Trvitron group company.
Ani Labsystems specializes in manufacturing of neonatal screening, cardiac, gastro, respiratory diagnostic kits and infectious disease testing products.
This acquisition will make Trivitron a global in vitro diagnostic company with the ability to manufacture variety of diagnostic kits covering all major areas of in vitro diagnostics field.
Trivitron Healthcare has also formed 49:51 JV with Italy-based DiaSorin Group to enter the immuno diagnostics market. The joint venture will be called DiaSorin Trivitron Healthcare Pvt Ltd which will cater to the Indian InVitro Diagnostics market of around $500 million and Indian immunodiagnostic market of around $165 million.
The company also raised around Rs 400 crore in a round led by Fidelity Growth Partners India which will be used to partially finance the acquisitions and to increase Trivitron’s shareholding in Kiran Medical Systems.
In this segment, Transasia Bio-Medical bought French company Maxmat SA, that specializes in conception, design, development and manufacturing of automated analyzers and reagents in the field of clinical chemistry, hemostatis and immunology. Also, American AB Sciex bought mass spectrometry business of LabIndia Instruments.
Trivitron is a global medical technology company focusing on manufacturing, innovation, distribution and after sales support. The company through its innovations and collaborative initiatives makes healthcare affordable and accessible to the emerging markets.
Bachem turns 50 - a timeline
Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.
1971 - beginnings
Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes.
1977 - 1981 - early growth
Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150.
1987 - 1996 - worldwide expansion
The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988.
Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance.
1998 - 2003 - Bachem goes public
Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients. By 2001, the company has 500 employees and sales reach 141 million CHF.
In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day.
2007 - 2013 - acquisitions
Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services.
In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion.
In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas.
2016 - 2019 - a global leader
In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K.
By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future.
2020 - COVID-19
Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and 272 new employees are hired.
2021 - a milestone anniversary
Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are plans to continue expanding.
Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."